Attovia Therapeutics
Update in progressATTO (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Attovia Therapeutics, Inc. is a clinical-stage biopharma company in San Carlos, California, developing immune‑mediated disease therapies in the United States. Using its ATTOBODY biparatopic platform, it creates novel biotherapeutics. Lead agents include ATTO-1310 (IL‑31 inhibitor for chronic pruritus), ATTO-2306 (IL‑13/IL‑31 inhibitor for atopic and skin diseases), and ATTO-1091 (TL1A/IL‑23/integrin a4ß7 triple inhibitor for IBD).
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.55
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!